Investment

Investing at the Intersection of Industrial Manufacturing and Healthcare

David Q. Anderson

Ampersand Capital Partners

Viral Vector Manufacturing

Accelerating The Development of Viral Vector Manufacturing Processes

Richard Snyder, Ph.D.; Clive Glover, Ph.D.; Rajiv Vaidya, Ph.D.; Matt Niloff

Thermo Fisher Scientific

Executive Q&A

Q&A: Building a Successful CDMO Brand

Ampersand Capital Partners

M&A

Brammer Bio Purchased by Thermo Fisher Scientific

Nice Insight

QPCR

Digital Droplet PCR for Viral Vector Analysis

Richard Snyder, Ph.D.; Susan D'Costa, Ph.D.; Sushma Ogram, Ph.D.; Diego Matayoshi

Thermo Fisher Scientific

Viral Vector Manufacturing

From Proof of Concept to Commercialization

Brammer Bio

Cell and Gene Therapy

Analytical Methodologies Utilized in Therapeutic Viral Vector Manufacturing

Richard Snyder, Ph.D.; Sushma Ogram, Ph.D.; Tony DeFusco

Thermo Fisher Scientific

Cell and Gene Therapy

Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing

Richard Snyder, Ph.D.; Christopher K. Murphy; Susan D'Costa, Ph.D.; Cameron Jones

Thermo Fisher Scientific

Viral Vector

Ensuring Confidence in Viral Vector Manufacturing

Michael Wourms; Christopher K. Murphy

Arranta Bio

Cell and Gene Therapy

Brammer Bio Completes Renovations at Manufacturing Site in Massachusetts

Nice Insight

Bioprocessing

Brammer Bio Leverages Advanced Bioprocessing Technologies to Accelerate Capacity

Nice Insight

Transient Transfection

Transient Transfection at a Large Scale for Flexibility in Clinical and Commercial Vector Manufacturing

Richard Snyder, Ph.D.; Scott Jeffers, Ph.D.; Ying Cai, Ph.D.

Thermo Fisher Scientific

CDMO

Supporting the Tech Transfer Continuum for Cell & Gene Therapies

Richard Snyder, Ph.D.; Matthew Caple; Jessica Tate, Ph.D.

Thermo Fisher Scientific

Investing for Successful Advancement of Viral Vector Manufacturing

Brammer Bio